This former pro football player rewrote his playbook on ATTR‑CM

Pete Shaw is a man with heart, and that passion drives everything—from the fighting spirit he brought to football to the abiding love he gives his family. Managing ATTR cardiac amyloidosis (also known as ATTR‑CM) is no different. With a strong team behind him, Pete is putting his heart into slowing the progression of this disease with AMVUTTRA® (vutrisiran).

Pete and Dr Mohan have been compensated by Alnylam for participating in Play by Play. Individual results may vary.

The pain riddled my body for years, but I thought it was football.

Watch the video to hear more from Pete Shaw, former pro football player living with ATTR-CM.

ATTR is easy to miss because many times it affects other parts of the body before it gets to the heart.

To hear more about ATTR-CM from Dr Mohan, the cardiologist who diagnosed Pete, watch the video.

I'm a fighter and I'm fighting this disease with AMVUTTRA.

Watch the video to hear more from Pete Shaw, former pro football player living with ATTR-CM.

He has his energy, not 100%, because we know that this disease is progressive, but each day is a gift.

To hear more from Kari, Pete's wife and caregiver, watch the video.

1 of 4

Learn more about ATTR amyloidosis and AMVUTTRA

How ATTR can lead to heart failure

When ATTR amyloidosis is left untreated, symptoms get worse over time and can lead to serious issues like heart failure.

Find out more about ATTR

How a TTR silencer works

AMVUTTRA is the first and only silencer for ATTR-CM and hATTR‑PN and reduces the production of TTR at the source, the liver.

Discover how it works

How AMVUTTRA helps people with ATTR‑CM

In the clinical study, people taking AMVUTTRA lived longer and had fewer heart-related hospital visits.*

Explore the results

*Most deaths were heart-related. Hospital visits included hospital stays and urgent visits.

Connect with a Patient Educator

A Patient Educator can provide disease education and answer questions about AMVUTTRA.

Sign up

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

ATTR amyloidosis
with cardiomyopathy (also known
as ATTR cardiac amyloidosis)​

hereditary ATTR
amyloidosis with polyneuropathy

transthyretin

transthyretin
amyloidosis

Kansas City Cardiomyopathy
Questionnaire

6-minute walk test

modified Neuropathy
Impairment Score +7

Quality of Life-Diabetic
Neuropathy